Prefilled Syringes Market Size, Share & Industry Analysis, By Material (Glass and Plastic), By Closing System (Staked Needle System, Luer Cone System, and Luer Lock Form System), By Product (Complete Syringe Set and Components & Accessories), By Application (Cancer, Rheumatoid Arthritis, Diabetes, and Others), By Design (Single-chamber, Double-chamber, and Multiple-chamber), By End User (Pharmaceutical & Biotechnology Companies, Contract Research & Manufacturing Organizations, and Others), and Regional Forecast, 2026-2034

The global prefilled syringes market size was USD 9.59 billion in 2025. The market is projected to grow from USD 10.57 billion in 2026 to USD 23.24 billion by 2034, exhibiting a CAGR of 10.3% during the forecast period.

A prefilled syringe is a container for drug delivery designed for the parenteral administration of drugs. There are several advantages associated with these syringes. Key advantages include reducing the risk of contamination, minimizing drug wastage, improving dosing accuracy, and enabling rapid and convenient administration. Due to the advantages mentioned above, pharmaceutical companies consider it one of the most effective means of providing a wide range of injectable drugs, including biological and non-biological drugs.

The burden of chronic conditions such as cancer and diabetes has been growing significantly. According to the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancer is expected to grow to 27.5 million new cases. According to the American Autoimmune Related Diseases Association Inc. (AARDA), about 50 million Americans suffer from autoimmune disorders currently. The growing burden of chronic conditions has been fueling the demand for effective drugs with advanced administration devices for regular and convenient administration.

BD, Stevanato Group, Gerresheimer AG, and SCHOTT Pharma are among the major market players focusing on partnership and collaboration to enhance their product offerings.  

Download Free sample to learn more about this report.

PREFILLED SYRINGES MARKET TRENDS

Shift from Glass to Polymeric Materials

The prefillable syringes market is experiencing a shift from glass to polymeric materials such as Cyclo Olefin Polymer (COP) due to the various advantages offered by COP, such as a high degree of break resistance, glass-like transparency, and very low oxygen permeation compared to other plastics. Moreover, these polymers offer advantages such as high chemical stability and design flexibility. The market has witnessed increased investment in the development of more stable resins.

Surge in the Demand for Homecare Treatment Options

Increased focus on self-injection and home-based treatment is significantly expanding the use of these syringes for chronic disease management.

Increasing Demand for Dual-chamber Syringes

Dual-chamber syringes are gaining popularity for lyophilized and combination drugs, particularly in North America and Europe.

Increasing Adoption of Advanced Technology for New Product Development

Advancements such as glass-plastic hybrid barrels, smart safety caps, and temperature-resistant materials drive product innovation.

Europe Prefilled Syringes Market Size, 2021-2034 (USD Billion)

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Increasing Demand for Biologics, Biosimilars, and Vaccines to Boost Market Growth

The growing preference for prefilled syringes for administering biologics and biosimilar products has been observed among healthcare providers and product development scientists owing to their advantages, such as improved convenience, dose accuracy, and self-administration. Prefilled syringes can also reduce costs associated with overfilling. Moreover, growing research and development activities and an increasing number of approvals of biologic products in prefilled-syringe presentations are driving market expansion.

• In March 2025, ANI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved purified Cortrophin Gel in a prefilled syringe.

This is expected to fuel the prefilled syringes market growth during the forecast period. 

MARKET RESTRAINTS

Strict Regulatory Requirements with Increasing Recalls of Prefilled Syringe Products Hinder Market Growth

Several regulatory authorities, such as the U.S. Food and Drug Administration (FDA), have stringent regulatory requirements for the approval of parenteral dosage forms. For the majority of the key players, the process of moving an injectable therapeutic to a prefilled syringe can be complex due to stability and sterility issues. Therefore, the key players must establish a strategy that carefully evaluates proposed changes in manufacturing, packaging, and shipping processes, and that ensures the validation of these changes on the therapeutic molecule to facilitate the smooth path to regulatory approval. The stringent regulatory requirements for prefilled syringes to maintain their stability, sterility, patient compliance, and smooth regulatory approval are projected to hamper the market growth of prefilled syringes during the forecast period.

Moreover, recalls of prefilled syringes due to the presence of particulate matter or stability issues, labelling issues, and more are also anticipated to negatively impact the demand for prefilled syringes during the forecast period. For instance, in August 2026, Fresenius Kabi issued a voluntary recall for one lot of Morphine Sulfate Injection, USP in a Simplist prefilled syringe due to a labeling mix-up.

MARKET OPPORTUNITIES

Increasing Focus of Market Players on Development of Technologically Advanced Products Creates Significant Market Growth Opportunities

Prefilled syringes are introduced into the market as an advanced delivery system for injectable drugs. Since their introduction, continuous improvement in syringe designs and component quality has been witnessed due to manufacturers' strong focus on developing user-friendly, advanced products.

• In January 2025, SCHOTT Pharma announced the launch of SCHOTT TOPPAC infuse polymer syringes, with an aim to improve safety, efficacy, and sustainability in healthcare.

Market players have been focusing on investing in the research and development of prefilled syringes to launch high-quality syringes with improved performance. This factor is expected to create significant market growth opportunities over the forecast period.  

MARKET CHALLENGES

Drug-Syringe Compatibility Issues and Higher Manufacturing Costs May Limit Market Growth

Prefilled syringes improve dosing accuracy, convenience, and administration efficiency. However, maintaining drug stability throughout shelf life remains a major challenge, particularly for sensitive biologics. Syringe components such as the barrel, plunger stopper, needle, adhesives, lubricants, and residual manufacturing materials remain in prolonged contact with the formulation and may affect product quality. Silicone oil, commonly used to enable smooth plunger movement, can migrate into the drug and contribute to subvisible particles or protein aggregation. Tungsten and adhesive residues may also create compatibility concerns for certain formulations.

Consequently, pharmaceutical companies must conduct extensive stability, extractables and leachables, container-closure integrity, and compatibility studies, increasing development timelines and costs.

For instance, in September 2024, Gerresheimer highlighted silicone-oil-free syringe systems as a way to reduce particle load for sensitive ophthalmic drugs and biologics. Moreover, ready-to-fill syringe manufacturing requires specialized molding, sterilization, surface treatment, inspection, and quality-control infrastructure, resulting in substantial capital investment requirements.

Segmentation Analysis

By Material

Glass Segment Dominated Market Due to Its Several Advantages

Based on material, the market is segmented into glass and plastic.

The glass segment held the largest prefilled syringes market share in 2025. Glass has remained the preferred choice of many pharmaceutical drug manufacturers for biological products, as the properties of glass material prevent the interaction between drug compounds and water vapor & oxygen. Such advantages associated with glass syringes are responsible for the segment's growth.

The plastic segment is anticipated to grow with a CAGR of 11.2% during the forecast period.

By Closing System

Increasing Adoption of Staked-Needle Systems to Boost Segment Dominance

By the closing system, the market is segmented into the staked needle system, luer lock form system, and luer cone system.

The staked needle system is likely to capture 42.2% of market share in 2026. The growing adoption of staked needle systems by healthcare providers during medical emergencies, due to various benefits such as simplified steps for the user and fewer chances of error during drug administration, is responsible for the segment's dominance.

The luer lock form system segment is expected to grow at a CAGR of 11.1% during the forecast period.

By Product

Rising Demand for Self-Injectable Delivery Systems among Patients Boosted Complete Syringe Set Segment Growth

Based on product, the market is segmented into complete syringe set and components & accessories.

The complete syringe set segment captured the largest share of the market in 2025, owing to the growing demand for these products for effective drug delivery and rising demand for self-injectable delivery systems among patients.

• For instance, in January 2023, Wirthwein Medical launched a complete syringe set with prefillable plastic syringes with a Luer-lock connection.

The components & accessories segment is expected to witness a CAGR of 8.3% in the coming years.

To know how our report can help streamline your business, Speak to Analyst

By Application

Rheumatoid Arthritis Segment Led Due to Growing Prevalence of the Disease

Based on application, the market is segmented into cancer, rheumatoid arthritis, diabetes, and others.

The rheumatoid arthritis segment is likely to hold 48.3% of market share in 2026. The segment's dominance is attributed to the disease's growing prevalence and the increasing focus of pharmaceutical companies on launching drugs indicated for rheumatoid arthritis treatment in prefilled syringes.

The cancer segment is expected to grow at the fastest CAGR of 11.5% during the forecast period.

By Design

Single-Chamber Segment to Lead Due to Increasing Commercialization and Advantages

Based on design, the market is segmented into single-chamber, double-chamber, and multiple-chamber.

The single-chamber segment is projected to capture a significant share of 82.1% of the market in 2026. The segment’s dominance is attributed to the advantages offered by single-chamber design for prefilled syringes to pharmaceutical & biotech companies. This design requires less overfill, resulting in less product waste, and aids in the ease of administration of the drug with its simple design model. Moreover, expanding commercial availability, technological innovations implemented in the filling procedures for single-chamber prefilled syringes, and the rise in the adoption of safety devices assembled in single-chamber prefilled syringes to reduce needlestick injuries among patients & healthcare providers are likely to boost the demand for the single-chamber segment during the forecast period.

• For instance, in January 2026, West Pharmaceutical Services, Inc. announced the global commercial availability of its West Synchrony S1 Prefillable Syringe System, offering 1 mL long and 2.25 mL staked-needle configurations for biologics and 1 mL staked-needle and Luer-lock configurations for vaccines.

The double-chamber segment is expected to grow at the fastest CAGR of 12.2% during the forecast period.

By End User

Growing Interest in Injectables to Boost Pharmaceutical & Biotechnology Companies Segment Expansion

Based on End User, the market is categorized into pharmaceutical & biotechnology companies, contract research & manufacturing organizations, and others.

The pharmaceutical & biotechnology companies segment is likely to capture a major share of 55.4% in 2026. The expanding pharmaceutical and biotechnology industries/companies across the globe are mainly engaged in biologics, vaccines, and biosimilars. These companies have increased their demand for new drug delivery systems, such as prefilled syringes containing a unit dose of medication for better patient compliance.

Moreover, the rising number of early-stage biotech players, along with government-funded biotech players, are focusing on drug discovery and development, which is likely to boost the demand for syringes for the effective delivery of drugs. The rise in demand for innovative injectable drug delivery systems is expected to boost the pharmaceutical & biotechnology companies' segment growth during the forecast period.

The contract research & manufacturing organizations segment is likely to expand at a CAGR of 11.2% during the forecast period due to innovative technologies offering filling services.

Prefilled Syringes Market Regional Outlook

Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Europe

To get more information on the regional analysis of this market, Download Free sample

Europe dominated the global market with USD 3.89 billion in 2025. The increasing number of patients using biologics as treatment options for chronic diseases and the strong adoption of advanced delivery methods for self-injection of drugs are the major factors likely to boost the demand in Europe. In addition, the presence of key players engaged in developing prefillable syringes in Europe is likely to boost market growth.

U.K. Prefilled Syringes Market

The U.K. market is projected to reach USD 0.45 billion in 2026, representing approximately 4.2% of global sales.

Germany Prefilled Syringes Market

Germany's market is expected to reach USD 1.21 billion in 2026, accounting for approximately 11.5% of global revenues.

North America

North America is projected to record a CAGR of 10.1% during the forecast period, the second-highest globally. The market is expected to reach USD 4.08 billion in 2026. This is attributable to the rising prevalence of chronic diseases such as diabetes and rheumatoid arthritis, which is likely to enhance the demand for prolonged drug administration at an accurate dosage, and the growing adoption of prefilled syringes by healthcare providers.

• For instance, according to the data published by the International Diabetes Federation, there were 38,536,400 total cases of diabetes in adults in the U.S. in 2024.

U.S. Prefilled Syringes Market

In 2026, the U.S. is anticipated to reach USD 3.85 billion, accounting for approximately 36.4% of global sales.

Asia Pacific

The Asia Pacific market is likely to be the third-largest market with a value of USD 1.62 billion in 2026 and witness fast-paced growth during the forecast period, mainly owing to the increasing prevalence of chronic and lifestyle diseases, rising usage of these syringes, and a rapidly growing patient population. Moreover, the rising awareness regarding innovations in these syringes and significant growth in contract manufacturing companies outsourcing packaging & filling services are likely to play a pivotal role in boosting the market growth in the region.

Japan Prefilled Syringes Market

Japan is projected to reach approximately USD 0.55 billion in revenue in 2026, representing nearly 5.2% of global sales.

China Prefilled Syringes Market

In 2026, China is anticipated to reach USD 0.50 billion, accounting for approximately 4.7% of global sales.

India Prefilled Syringes Market

In 2026, India is anticipated to reach USD 0.15 billion, accounting for approximately 1.4% of global sales.

Latin America and Middle East & Africa

Latin America is likely to be the fourth-largest market with a value of USD 0.34 billion in 2026, and the Middle East & Africa region is likely to experience slow growth in this market due to lower awareness of innovative products and slow market penetration.

GCC Prefilled Syringes Market

The GCC market is expected to hit USD 0.16 billion in 2026, accounting for 1.5% of global sales.

COMPETITIVE LANDSCAPE

Key Industry Players

Strong Product Offerings by Key Players to Propel Market Growth

BD, Stevanato Group, Gerresheimer AG, SCHOTT Pharma, and West Pharmaceutical Services, Inc. were among the leading players in the global prefilled syringes market in 2025. Leading companies are strengthening their market positions through product innovation, capacity expansion, strategic collaborations, and the development of advanced syringe platforms.

• For instance, in January 2026, BD and Ypsomed expanded their partnership to develop a 5.5 mL version of the BD Neopak XtraFlow Glass Prefillable Syringe, addressing the increasing need for higher-volume subcutaneous administration of biologic therapies.

Other prominent players in the market, such as West Pharmaceutical Services, Inc., Aptargroup, Inc., and Ypsomed AG, have been focusing on the development and launch of prefilled syringes to enhance their offerings in the market.

LIST OF KEY PREFILLED SYRINGE COMPANIES PROFILED

• BD (U.S.)
• SCHOTT Pharma (Germany)
• Gerresheimer AG (Germany)
• West Pharmaceutical Services, Inc. (U.S.)
• NIPRO (Japan)
• AptarGroup, Inc. (U.S.)
• Terumo Corporation (Japan)
• Ypsomed AG (Switzerland)
• Datwyler Healthcare ((Switzerland))
• Stevanato Group (Italy)

KEY INDUSTRY DEVELOPMENTS

• July 2026: Gerresheimer AG announced an agreement to sell Centor and its global Primary Packaging Plastics business to Apax Funds.
• January 2026: BD and Ypsomed expanded their collaboration around the new 5.5 mL BD Neopak XtraFlow Glass PFS, designed for integration with YpsoMate 5.5.
• October 2025: Terumo Corporation completed the acquisition of a drug-product manufacturing facility in Leverkusen, Germany, previously owned by WuXi Biologics, establishing its first overseas CDMO production site.
• April 2025: Gerresheimer AG and Injecto Group expanded their cooperation through a supply and license agreement covering patented plunger-stop technology.
• January 2025: SCHOTT Pharma launched the next generation of SCHOTT TOPPAC infuse polymer syringes, a system designed to improve safety, efficiency, and sustainability in healthcare in the global market.
• December 2024: Gerresheimer AG announced the expansion of its production capacity in Skopje, North Macedonia, with a new production hall for syringes.

REPORT COVERAGE

The global prefilled syringes market report provides detailed information and insights into the market. Some of these include growth drivers, restraints, competitive landscape, regional analysis, and challenges. It further offers an analytical depiction of the market trends and estimations to illustrate the forthcoming investment opportunities.

Request for Customization   to gain extensive market insights.

Report Scope and Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1: Revenues and Market Share of Major Prefilled Syringe Players

• Collection of prefilled syringe-related revenues from annual reports, SEC filings, investor presentations, and company disclosures of major players such as BD, SCHOTT Pharma, Gerresheimer AG, Stevanato Group, Nipro Corporation, and other manufacturers.
• Estimation of company market shares based on syringe revenues, production capacity, geographic presence, product portfolio, customer base, and manufacturing expansion.
• Triangulation of company-level revenues with regional demand, production capacity, and syringe utilization to derive the global market estimate.

Approach 2: Product-Level Sales and Volume Analysis

• Identification of major prefilled syringe products across glass and polymer formats, along with conventional and advanced syringe configurations.
• Collection and estimation of annual unit shipments, production volumes, product mix, and average selling prices of major manufacturers.
• Estimation of market value by multiplying prefilled syringe volumes with manufacturer-level ASPs across countries and regions.
• Assessment of new production lines, capacity additions, product launches, and adoption of advanced biologic-compatible and large-volume prefilled syringes.

Approach 3: Injectable Drug and Prefilled Syringe Utilization Model

• Assessment of injectable drug volumes across biologics, GLP-1 therapies, vaccines, anticoagulants, insulin/diabetes therapies, autoimmune therapies, and other injectable drugs.
• Estimation of the proportion of injectable therapies delivered through prefilled syringes versus vials, cartridges, and other delivery formats.
• Analysis of self-administration, autoinjector adoption, biologics penetration, treatment frequency, and patient volumes.
• Regional prefilled syringe volumes were multiplied by applicable ASPs, and regional estimates were summed to derive the global market.

2. Top Down Approaches

Approach 4: Analysis of Parent and Adjacent Markets

• Analysis of the injectable drug delivery, primary pharmaceutical packaging, and parenteral drug delivery markets, followed by estimation of the share attributable specifically to prefilled syringes.
• Validation using injectable drug volumes, biologics penetration, prefilled syringe adoption rates, pharmaceutical production, and regional healthcare expenditure.
• The summation and reconciliation of regional estimates were used to validate the global prefilled syringes market.

3. List of Key Sources

• Annual reports, SEC filings, investor presentations, earnings releases, and sustainability reports of key manufacturers.
• FDA, EMA, PMDA, NMPA, WHO, CDC, OECD, World Bank, Eurostat, and national health authorities.
• Product catalogs, regulatory approvals, product registrations, patent filings, production-capacity announcements, and company press releases.
• Pharmaceutical prescription and injectable drug utilization statistics.
• Clinical guidelines and publications relating to biologics, diabetes, vaccines, anticoagulants, autoimmune diseases, and self-injectable therapies.
• Import/export and pharmaceutical manufacturing statistics where applicable.

5. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents:
  • Prefilled syringe manufacturers, pharmaceutical packaging suppliers, contract manufacturers, distributors, sales executives, marketing managers, business development managers, and other industry participants.
  • Interviews focused on market size, pricing, production capacity, product mix, competitive shares, regional demand, and future growth trends.

Demand Side Interviews: 40%

• Key Respondents:
  • Pharmaceutical and biotechnology companies, drug-device combination product developers, fill-finish providers, hospitals, procurement professionals, and healthcare providers.
  • Interviews focused on prefilled syringe adoption, injectable drug volumes, preferred syringe formats, purchasing patterns, ASPs, self-administration trends, and regional demand.